Abstract

This paper on the biological tests carried out on serum/plasma samples from donors of human body material (HBM) is the result of a project of the working Group of Superior Health Council of Belgium formed with experts in the field of HBM and infectious serology. Indeed, uncertainty about the interpretation of biological test results currently leads to the sometimes unjustified cancelling of planned donations or the rejection of harvested HBM, whilst more sophisticated diagnostic algorithms would still allow the use of organs or HBM that would otherwise have been rejected. NAT tests will not be discussed in this publication. In the first part some general aspects as the need for a formal agreement between the Tissue Establishment l and the laboratory responsible for the biological testing, but also some specifications regarding testing material, the choice of additional biological tests, and some general aspects concerning interpretation and reporting are discussed. In a second part, detailed information and recommendations concerning the interpretation are presented for each of the mandatory tests (human immunodeficiency virus, hepatitis B virus, hepatitis C virus and syphilis) is presented. A number of not mandatory, but regularly used optional serological tests (e.g. for the detection of antibodies to Toxoplasma gondii, Epstein–Barr virus, human T cell leukemia virus and cytomegalovirus) are also extensively discussed. Although the project was meant to provide clarification and recommendations concerning the Belgian legislation, the majority of recommendations are also applicable to testing of donors of tissues and cells in other (European) countries.

Highlights

  • Belgium sophisticated diagnostic algorithms would still allow the use of organs or human body material (HBM) that would otherwise have been rejected

  • This paper looks at screening for HTLV-1 antibodies, CMV, toxoplasmosis and EBV as examples for such additional serological tests

  • A number of practical recommendations have been formulated with the intention to make progress in the standardization of in particular testing, interpretation of biological tests on blood samples of potential donors of human body material

Read more

Summary

Introduction

Carrying out additional HIV NAT testing reduces the ‘‘window period’’ after a possible HIV infection with additional 3–4 days compared to the 4th generation anti-HIV 1/2 serological tests described above, which enhances the safety of HBM donation. For the most recent new anti-HCV tests, such a cut-off value for potentially false-positive results has not (yet) been verified (CDC 2015b) sophisticated serological and NAT tests have become available in recent years to screen for HIV and hepatitis B and C.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call